Victims of fear and misunderstanding

ProhostLetter #423
For a more or less fair evaluation of biotechnology and pharmaceutical firms, analysts currently rely for their assessment on criteria that include quarterly financial results, products’ sales revenues, and year over year growth of each and every marketed therapeutic. When it comes to clinical-stage firms, the logic implies that these criteria cannot be relied on for evaluation, as most of the development-stage firms have no revenues or incomes, hence, these firms are downgraded after each and every quarterly release of their financial results . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.